# NPPA caps trade margins on 137 anti-cancer drugs from November 9 2026-11-02T09:31:51+00:00 | Governance | Indian Opinion Desk Corroboration: 3 independent outlets The National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% of the maximum retail price (MRP) for 137 non-scheduled anti-cancer drugs, effective from 9 November. The order follows a Supreme Court question in September 2026 about a tenfold gap between manufacturer prices and patient prices. The government expects MRPs to fall by up to 70% and estimates annual patient savings of about Rs 2,500 crore, with Livemint reporting a range of Rs 2,500 to 3,500 crore. The NPPA’s market analysis found the average mark-up on non-scheduled cancer drugs was about 170%, with the highest at 700%. The margin cap applies only to intermediaries in the supply chain, not to manufacturer prices, and excludes patented or innovative medicines. The revised price list reflects data submitted by companies up to 27 October and will be updated as manufacturers comply. The NPPA has required manufacturers to report revised prices within seven days. Update, 2 November 2026: Livemint reports the NPPA slashed MRPs for 543 anti-cancer medicine brands, not just 137 drugs, and cites a higher annual savings estimate of Rs 2,500 to 3,500 crore from official documents. It also names specific drugs including immunotherapy medicines and lists Bevacizumab as among those covered. ## Indian Opinion Analysis All three outlets report the NPPA margin cap as fact, but they differ in scope and emphasis. The Hindu leads with the Supreme Court’s September query and frames the policy as an answer to a regulatory question. Times Now and Livemint both cite the government’s estimated savings of Rs 2,500 crore, Livemint adds a higher range of Rs 2,500 to 3,500 crore, drawn from official documents. Times Now is the only source to discuss the broader affordability chain, from R&D to QR-code traceability from July 2027, essentially treating the cap as one step among many. Livemint lists specific drugs and provides a direct quote from the ministry release, making it the most concrete. No outlet criticises the cap itself. The uniform core is the 30% margin, effective 9 November, the differences are in whether the story is presented as regulatory closure, patient-saving estimate, or long-term roadmap. ## Coverage Coverage: 3 sources, 3 neutral - thehindu.com (neutral report) Leads with SC query, frames as regulatory response - timesnownews.com (neutral report) Adds broader affordability context and future steps - livemint.com (neutral report) Cites higher savings estimate and lists specific drugs This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Tags: Cancer drugs, NPPA, Supreme Court, trade margin cap Canonical: https://indianopinion.org/nppa-caps-trade-margins-on-137-cancer-drugs-at-30-from-9-november/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/nppa-caps-trade-margins-on-137-cancer-drugs-at-30-from-9-november/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/